Global Angina Pectoris Drugs Market – Industry Trends and Forecast to 2029

Angina Pectoris Drugs Market Analysis and Size

The global angina pectoris drugs market is witnessing a high growth during the forecast period. The rising cases of heart related disorders boosts the angina pectoris drugs market. Several factors such as increased stress , presence of coronary artery disease, diabetes and hypertension alongwith family history boost the angina pectoris drugs market growth. In addition to this, COVID-19 also had a significant impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global angina pectoris drugs market in the forecast period 2022-2029. The expected CAGR of global angina pectoris drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 9.0 billion in 2021, and it would grow upto USD 13.81 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Angina pectoris is a type of heart condition that is characterized by narrowing of coronary arteries that leads to reduction in blood flow to the heart. Symptoms include chest pain, dizziness, fatigue, discomfort, nausea, shortness of breath and sweating. Antianginal drugs prevent, abort or terminate attack of angina pectoris. These drugs helps in reducing oxygen demand, increase the oxygen delivery to the myocardium and also inhibit the calcium channels and platelet aggregation.

Angina Pectoris Drugs Market Scope and Segmentation

Global Angina Pectoris Drugs Market Dynamics

Drivers

• Increasing Prevalence of Chronic Angina Pectoris

Chronic stable angina pectoris is found to have a prevalence of 2.0 - 4.0% in the seven major markets  namely U.S., U.K., France, Italy, Germany, Spain, Japan. Heart Disease and Stroke Statistics from the American Heart Association indicated that over 9 million adults in the U.S. have chronic angina pectoris.  This boost the market growth.

• Rising Drug Approvals and Clinical Research

Increased approvals from FDA and more clinical research associated with angina pectoris are boosting the market growth. For instance, multiple gene therapy products in Phase II/III trials are developing as a novel approach towards addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector DNA-based gene therapy is going through late-stage clinical trials and could present as a promising growth opportunities for the market in the upcoming years.

Opportunities

• Increasing Demand for Retail Pharmacies

Rise in the number of cortical necrosis therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global angina pectoris drugs market over a forecast period.

• High Cost

The huge expenditure associated with the treatment of angina pectoris surely hamper the market growth.

This global angina pectoris drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global angina pectoris drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Angina Pectoris Drugs Market          

The demand for angina pectoris drugs is likely to grow with the rising implications of heart disease among COVID-19 patients. The number of cardiovascular patients entering into the emergency rooms has reduced in the case of COVID-19. Patients with angina pectoris started to avoid going to emergency rooms because they were afraid of becoming infected with the virus. All these factors negatively impacted the market growth but slowly the market is set to rise due to the decrease in COVID-19 patients.

Global Angina Pectoris Drugs Market Scope

The global angina pectoris drugs market is segmented on the basis of type, drugs, route of administration , distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Stable Angina
• Unstable Angina
• Prinz-metal’s Angina

Drugs

• Nitrates
• Antiplatelet Agents
• Beta-adrenergic Blocking Agents
• Calcium Channel Blockers
• Anti-ischemic Agents
• Statins
• Antihypertensive Agents
• Others

Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Angina Pectoris Drugs Market Regional Analysis/Insights

The global angina pectoris drugs market is analysed and market size insights and trends are provided by type, type, drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global angina pectoris drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global angina pectoris drugs market due to high prevalence of diabetes & hypertension in densely populated countries and rapidly improving health care infrastructure in the region.

North America dominates the market due to increased prevalence of chronic heart disease, and technological advancements in early diagnosis of the disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Angina Pectoris Drugs Market Share Analysis

The global angina pectoris drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global angina pectoris drugs market

Key players operating in the global angina pectoris drugs market include:

• AERIE PHARMACEUTICALS, INC. (U.S.)
• Abbvie, Inc (U.S.)
• Bausch Health Companies, Inc (U.S.)
• Merck & Co. Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Amorphex Therapeutics Holdings, Inc (U.S.)
• Alcon (Switzerland)
• Astellas Pharma Inc. (Japan)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Amgen Inc. (U.S.)
• Carl Zeiss Meditec AG (Germany)
• Gilead Sciences, Inc.(U.S.)
• Sun Pharmaceutical Industries Ltd (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)

SKU-53883